Physician profile
David I Somerman
NPI 1255586178
$8,043.10
in general payments reported to CMS, 2019-2025
16 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,808 · 2020: $2,414 · 2023: $250 · 2024: $117 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $7,092.79 | 2019-2025 | Ultomiris |
| Amgen INC. | $275.96 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $142.15 | 2023-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $124.99 | 2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $72.01 | 2025 | |
| Travere Therapeutics, INC. | $65.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $53.67 | 2025 | |
| Akebia Therapeutics INC | $51.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $29.98 | 2024 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.13 | 2025 | |
| Mallinckrodt Hospital Products INC. | $25.83 | 2025 | Terlivaz |
| Opko Pharmaceuticals, LLC | $24.49 | 2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $21.66 | 2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.37 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.13 | 2024 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Somerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.